boxes as to the proof of protection against sars-cov-2 delta variant. there was one glaring missing check in previous iterations of this and that was in the j&j clinical effectiveness. next slide. i had showed you before this slide looking at data of immune responses in vitro and this was the j&j vaccine study, which showed that it elicits durable antibody and cellar responses against delta with minimal decreases for at least eight months after immunization. next slide. we now have a slide that recently a study that recently came out from south africa and other southern african countries. it s called the sisonke study including health care workers, this is real world effectiveness against delta with a 91 to 96%
Το μονοδοσικό εμβόλιο της αμερικανικής Johnson Johnson είναι σε ικανοποιητικό βαθμό αποτελεσματικό κατά της πιο μεταδοτικής και ολοένα εξαπλωνόμενης παραλλαγής Δέλτα του κορωνοϊού, χωρίς να χρειάζεται ενισχυτική δόση, σύμφωνα με μια νέα μεγάλη μελέτη σε περίπου 480.000 υγειονομικούς στη Νότια Αφρική, ενώ ηΙνδία ενέκρινε σήμερα, το εμβόλιο μιας δόσης της Johnson Johnson (JJ) κατά της COVID-19 για έκτακτη χρήση.
We d be thrilled if HIV and TB got this much attention, says Sisonke trial leader 09 June 2021 - 16:14 Prof Linda-Gail Bekker, right, with Prof Glenda Gray, left, carrying the first dose of vaccine for the Sisonke study that kickstarted SA s Covid-19 vaccinations. Image: File photo
Prof Linda-Gail Bekker, co-lead investigator on the Sisonke trial, has cautioned that we drop the ball on HIV and tuberculosis at our peril as we battle Covid-19.
Speaking at the Cape Town Press Club on Wednesday, she said: “It is 40 years this week since HIV was first described in gay men on the west coast of America and we are still looking for a safe prophylactic against the virus. I have spent most of my adult career as a scientist looking for that vaccine.”